May 9 |
Monopar Therapeutics GAAP EPS of -$0.10
|
May 9 |
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
|
Apr 18 |
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
|
Apr 16 |
Monopar files patent protecting its MNPR-101 radiopharma optimization findings
|
Apr 16 |
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
|
Apr 10 |
Monopar initiates radiopharma phase 1 trial for its advanced cancer treatment
|
Apr 10 |
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
|
Apr 4 |
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|
Apr 3 |
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy
|